Latest / CME Outfitters Medical Education / Fibrosis in IBD — Pathogenesis, Risk Stratification, and Objective Monitoring
Transcript
- 0:01SPEAKER_01: Hello, I'm Amr Nayak.
- 0:03SPEAKER_01: On behalf of CME Outfitters, I would like to welcome you and thank you for joining us for today's podcast entitled Fibrosis and IBD: Pathogenesis, Risk Stratification, and Objective Monitoring.
- 0:14SPEAKER_01: Today's program is supported by an independent educational grant from Merck Company Incorporated in Rowe, New Jersey, USA.
- 0:21SPEAKER_01: This activity may include discussions of products or devices that are not currently labeled for use by the U.S.
- 0:27SPEAKER_01: Food and Drug Administration or the FDA.
- 0:30SPEAKER_01: The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses, which are any uses not approved by the FDA of products or devices.
- 0:44SPEAKER_01: Before we begin, I'd like to read our learning objectives.
- 0:49SPEAKER_01: After listening to our podcast, learners will be able to evaluate biological mechanisms contributing to fibrosis and IBD, identify clinical features and disease behaviors associated with fibrotic progression, and importantly, apply objective monitoring strategies to assess structural disease progression.
- 1:09SPEAKER_01: Evaluate, identify, apply.
- 1:12SPEAKER_01: Alright, well, I'd like to welcome everyone to episode two of the Hidden Burden of IBD series.
- 1:19SPEAKER_01: Like to say, there's a lot of F-words in IBD, and uh most of them are the ones we don't talk about enough, let alone some may permeate through on a day-to-day basis.
- 1:28SPEAKER_01: But the ones I'm I'm speaking of today are fibrosis, fistula, flares, failure of therapy, fatigue, functional impairment.
- 1:39SPEAKER_01: Today we're focusing on all the one main other ones, and with Dr.
- 1:42SPEAKER_01: Fleshner and and um and Dr.
- 1:44SPEAKER_01: Harmouth, focusing on fibrosis.
- 1:47SPEAKER_01: So fibrosis.
- 1:49SPEAKER_01: This drives all other problems.
- 1:51SPEAKER_01: The structural scarring that accumulates even when inflammation looks controlled, that eventually obstructs the bowel and brings patients to the OR or the operating room.
- 2:01SPEAKER_01: Joining me are Dr.
- 2:02SPEAKER_01: Carla Harmouth, a radiologist at the University of Chicago who specializes in IBD imaging, and Dr.
- 2:09SPEAKER_01: Philip Fleshner, a colorectal surgeon at Cedar Sinai.
- 2:12SPEAKER_01: Welcome to you both.
- 2:17SPEAKER_03: Great to be here.
- 2:18SPEAKER_03: Thanks for having us.
- 2:19SPEAKER_01: All right, well, thanks.
- 2:21SPEAKER_01: Happy to have this conversation with you all today.
- 2:23SPEAKER_01: And uh, if I may, Phil, um, before we even get to the science, can you just I want to start with you and take us through when a patient arrives for a surgery?
- 2:34SPEAKER_01: What do you see that the referring team didn't didn't see or didn't appreciate?
- 2:40SPEAKER_02: Well, thanks for having me, first of all.
- 2:41SPEAKER_02: And I think probably the most important thing is the lack of appreciation on behalf of on our GI docs of how this is a long-term problem.
- 2:51SPEAKER_02: This is not just giving advanced therapies and seeing how the patient does.
- 2:56SPEAKER_02: And what tends to happen is that the medications are given and they're given multiple times, with quite frankly, sometimes marginal improvement, but the GI doc continues to do this.
- 3:06SPEAKER_02: And by the time we end up seeing this as a long-term issue for the patient, they end up being malnourished, they end up being on pain medication, they end up being on narcotics, and like I just mentioned, they end up being on steroids, and and quite frankly, medications that interfere with potential surgical healing.
- 3:24SPEAKER_02: And therefore, what happens is that they there was no appreciation of the fact that, hey, maybe this patient needed surgery earlier on, before this patient came in, that literally was a train wreck by the time we got them.
- 3:36SPEAKER_01: Yeah, sometimes it might feel like you have a you have a time machine to hop into a DeLorean, go back a year or two before uh they actually saw you.
- 3:44SPEAKER_01: So sometimes it's it's the timing that seems to be what I'm guessing, what I'm lifting here from that.
- 3:49SPEAKER_01: And and uh not to make light of it, but sometimes more cowbell isn't what you need.
- 3:53SPEAKER_01: And and medications are just one part of our treatment of a lifelong condition that we have no cure for yet.
- 3:59SPEAKER_02: Um, the way that I like the way that I like to figure it, if I can interrupt, is that you have to think of something called colorectal mab.
- 4:06SPEAKER_02: Okay, this is colorectal, not just you know the mabs that you guys know.
- 4:11SPEAKER_02: This is colorectal mab, which in many ways might be the best MAB, quite frankly, because as you know, it's the highest incidence of at least induced remission pretty quickly.
- 4:19SPEAKER_01: Yeah, no, that's uh I like that one.
- 4:22SPEAKER_01: I like the one.
- 4:22SPEAKER_01: I I used to have a little bit uh in in life called exercise you mab, but that kind of rolls right into colorectumab and and operations that are are really uh a huge, huge important um and and misguided thing here.
- 4:35SPEAKER_01: And and embracing that when necessary is something that uh I see a lot of struggle with in in the community of knowing when, knowing when to ask for help.
- 4:44SPEAKER_01: And is it is it correct to think if I'm thinking about it, I ought to talk to someone about it?
- 4:51SPEAKER_01: Is that correct in the sense that you see more communication can be done in the community and in even academia?
- 4:57SPEAKER_02: Yes, I think very much so.
- 4:59SPEAKER_02: Um but you know, as you know, I mean, you know, GI docs work in their own silos, and quite frankly, colorectal surgeons work in their own silos.
- 5:07SPEAKER_02: In the place that I'm at, we actually don't silo like that.
- 5:10SPEAKER_02: And because of that, we communicate with each other very quickly.
- 5:13SPEAKER_02: And many times, quite frankly, the GI docs say they need patients need surgery, I say no, or even the other way around.
- 5:19SPEAKER_02: So that's where it really comes uh as in terms of like just practical day-to-day stop working in silos.
- 5:25SPEAKER_02: That's that's very, very bad for patient care.
- 5:27SPEAKER_01: Absolutely.
- 5:28SPEAKER_01: I think teamwork makes that dream work and and not to Carl and not to ignore that speaking of silos and no pun intended and and and in the dark, but how can how can how can our surgeons and our gastroenterologists and our radiologists work together and how can we make that bridge a little better?
- 5:44SPEAKER_03: Uh this this is the main thing, I think, for any disease, blood inflammatory bowel disease, uh in particular, multidisciplinary approach, right?
- 5:53SPEAKER_03: We have to get out of our silence.
- 5:55SPEAKER_03: I think all of us have important information about those patients.
- 5:58SPEAKER_03: And if we dig a little bit, we can find that information.
- 6:01SPEAKER_03: So, yes, communication, talk to your radiologist.
- 6:04SPEAKER_03: What type of imaging can you do?
- 6:05SPEAKER_03: And what can I give you?
- 6:06SPEAKER_03: What type of information can I give you?
- 6:08SPEAKER_03: There's some things I can tell you, some things I cannot, and some things that we can figure out together with the input of the clinician, surgeon, lab findings, and my imaging.
- 6:18SPEAKER_01: Oh, that's great.
- 6:19SPEAKER_01: I I like I like this whole teamwork together.
- 6:21SPEAKER_01: And and I think that this is the way that we can potentially solve uh a lot of problems and a lot of unnecessary uh therapeutic misadventures, perhaps, um, and really focus on fibrosis is something that probably we haven't done a good enough job of.
- 6:34SPEAKER_01: And I hope this can help bring this to the light and that gets us thinking.
- 6:37SPEAKER_01: And really the biology of fibrosis, from that standpoint, the numbers are striking.
- 6:41SPEAKER_01: This is a real problem.
- 6:42SPEAKER_01: This occurs.
- 6:43SPEAKER_01: And up to 70% of people with Crohn's develop stricturing or penetrating compliance complications within 10 years, and that's bowel damage from inflammation, damage that has occurred already, and damage that needs to be fixed.
- 6:55SPEAKER_01: So 40 to 70 percent require surgery within a decade of diagnosis, and a decade's 10 years.
- 7:01SPEAKER_01: And we could probably crunch that down to even sooner and find out those people early on who may benefit.
- 7:05SPEAKER_01: There are zero gobsmacking, zero FDA-approved antifibrotic therapies for IBD, despite the burden we just talked about.
- 7:16SPEAKER_01: And so here's why.
- 7:17SPEAKER_01: You know, chronic immune activation drives mesenchymal cell activation, which drives excess extracellular matrix deposition and remodeling.
- 7:25SPEAKER_01: And then once that remodeling starts, guys, it's a self-perpetuating mess.
- 7:29SPEAKER_01: It's like when inflammation looks controlled on paper and certain certain things that we have kind of hung our hat on and been falsely reassured with, um, we can sometimes losing lose track.
- 7:39SPEAKER_01: And so, Carla, from this, take us take us down this journey from the imaging side from your aspect.
- 7:44SPEAKER_01: What does established fibrosis, what does it mean to you?
- 7:47SPEAKER_01: What does it actually look like by the time it ends up on your screen in your reading room under your guys?
- 7:54SPEAKER_03: So let me just start by saying that you know, some of those biological events, uh, you know, they are uh happening.
- 8:00SPEAKER_03: We cannot, we do not have the resolution to see it yet.
- 8:03SPEAKER_03: But by the time it's fibrotic, there are a few things that we can have a high suspicion in imaging that is not gonna improve just medical treatment.
- 8:12SPEAKER_03: If the bowel wall is too thick, and preferably if you have longitudinal evaluation, right?
- 8:17SPEAKER_03: If I image this patient last year and I'm re-imaging him this year and you know, things are getting worse.
- 8:24SPEAKER_03: The bowel is getting more dilated, the wall is thick, but that edema, the inflammation that I can see, especially with MRI, is no longer there.
- 8:32SPEAKER_03: You know, the signal of the wall has changed.
- 8:36SPEAKER_03: These are things that I look for, you know, bowel stasis, you know, if I have fecal contents in the small bowel, this to me means that you know the bowel is slow, you know, like it's not progressing as it should.
- 8:48SPEAKER_03: Uh, is there a dilatation associated with that area of narrowing?
- 8:52SPEAKER_03: So these are things that I try to see.
- 8:55SPEAKER_03: And by the time they get to me with that already, then it's usually a patient that will need a surgical consultation rather than just medication.
- 9:04SPEAKER_01: So it's it's fascinating.
- 9:05SPEAKER_01: We think of fibrosis as something you see on a pathology specimen or something you may recognize.
- 9:10SPEAKER_01: But you're telling me at least it seems like there are features and things that maybe clues that even today, prior to the advancement of this of the field, that we can actually kind of recognize and see from an imaging standpoint.
- 9:22SPEAKER_01: I mean, I think that's I think that's very helpful in us to kind of plan you know our next treatment approach.
- 9:27SPEAKER_01: I mean, taking this step back, you know, there's been a lot in the GI world about, all right, treat to target, heal the mucosa.
- 9:35SPEAKER_01: You know, and when this patient achieves this healing of the mucosa, so to speak, like it's like the like the magical thing.
- 9:42SPEAKER_01: What are you worried about when when that the endoscopy may not be telling you if something, if someone claims that there's mucosa healing feels, is there something that that we may have missed when we just talk about that in this overly simplistic manner?
- 9:53SPEAKER_02: Very much so.
- 9:54SPEAKER_02: I mean, I I think just sort of what you said, I said once the process starts, you're looking at a bowel, you're looking at a mucosa.
- 10:02SPEAKER_02: Remember, there's a lot more to this section than just what you're looking at at the mucosal level.
- 10:06SPEAKER_02: There's the bowel wall with muscle, and there's also creeping fat behind it, which many of you know creeping fat is an incredibly uh almost pathonomonic finding in patients with Crohn's disease.
- 10:17SPEAKER_02: So what's happening is that even though you know the the GI doc looks and said, Oh, I have mucosal healing, but yet, you know, the patient's still strictured.
- 10:24SPEAKER_02: The patient's having malnutrition, patient's vomiting, makes surgery more difficult.
- 10:28SPEAKER_02: Also, what happens is the creeping fat continues.
- 10:31SPEAKER_02: When the creeping fat continues, it makes my life as a surgeon difficult, which obviously then translates, translates to a more difficult surgery, obviously, for the patient.
- 10:39SPEAKER_02: So it's not just treat the target what you're seeing on the mucosal level.
- 10:43SPEAKER_02: It's actually treating the target through the bowel wall and even to the creeping fat.
- 10:49SPEAKER_01: I like that.
- 10:49SPEAKER_01: What lies beneath um in terms of getting getting in there and seeing what's what's driving all of that uh surface, just things on the surface that can can mislead.
- 10:59SPEAKER_01: It's that's that's a I think that's a great, that's a great point and something that we're we're still developing and embracing in terms of as we get to our our our our treatment goals, so to speak.
- 11:09SPEAKER_01: And I I think it's fascinating because TL1A sits at the intersection of what's being referred to as this immunofibrosis, this concept that inflammation and fibroblast activation are not sequential, but simultaneous drivers of disease.
- 11:24SPEAKER_01: So not a backseat driver.
- 11:26SPEAKER_01: This is someone that's driving alongside with you.
- 11:28SPEAKER_01: This TL1A is the only cytokine really known to do both at once, makes it uniquely interesting as a therapeutic potential therapeutic target.
- 11:35SPEAKER_01: And Talissa Cobart, an investigational anti-TL1A, a monoclonal antibody, recently became the first anti-TL1A agent to meet primary endpoints in the phase three UC trial, the Atlas UC study.
- 11:47SPEAKER_01: And I and we talked a lot about Crohn's, but I guess I guess there's damage, bowel damage in ulcerative colitis as well.
- 11:52SPEAKER_01: Um, you know, and phase three phase three results in Crohn's are still pending.
- 11:55SPEAKER_01: Carla Phil, does this immunofibrosis biofibrosis biology, excuse me, change how you think about what you're seeing in practice?
- 12:01SPEAKER_01: I mean, there's ulcerative colitis too, right?
- 12:05SPEAKER_03: Yes.
- 12:05SPEAKER_03: Uh I I think, you know, the fact that they coexist in a lot of uh cases uh clears up what we see and correlates with imaging.
- 12:14SPEAKER_03: A lot of times we do have both patterns, you know, areas that have some more of an inflammatory appearance with edema of the wall rather than that low T2 signal which we favor to be fibrosis or muscle hypertrophy.
- 12:26SPEAKER_03: So that actually uh makes sense, makes perfect sense.
- 12:30SPEAKER_02: The only thing I would add, Amar, is that you know, it's uh there's no question that this is playing a role.
- 12:35SPEAKER_02: The question is, what are we seeing?
- 12:36SPEAKER_02: How is it influencing what we're doing in practice yet?
- 12:39SPEAKER_02: We don't know because we don't really have a lot of the data yet.
- 12:42SPEAKER_02: But it'll be very interesting to speculate really if these drugs work.
- 12:46SPEAKER_02: Are we gonna see, for example, a patient who's initially diagnosed with a B1 phenotype not progress on to a B2 or B3, maybe not a B3 phenotype as an example?
- 12:55SPEAKER_02: Okay, are we gonna see patients who had iliocolic resections, like what I do with surgery, which obviously would then potentially lead to fibrosis in the wall and occurrence strictures?
- 13:05SPEAKER_02: Would these medications potentially as prophylactic medication prophylaxis reduce the chance of recurrence?
- 13:11SPEAKER_02: And I'm also quite frank, even though we're mainly talking about fibrosis and strictures and Crohn's disease, it'd be very interesting to know what would happen to these medications if they're given to patients who have ileal pouches.
- 13:21SPEAKER_02: Are we going to potentially see a reduce of pouchitis, de novo Crohn's disease, fibrosis in the wall of the ileal pouch?
- 13:28SPEAKER_02: So these are all questions that are very exciting.
- 13:30SPEAKER_02: We obviously don't know that you know where they are yet, but they're very, it's an exciting time to see these types of medications coming on board.
- 13:37SPEAKER_01: Yeah, the pouch patients are fascinating, right?
- 13:39SPEAKER_01: Because we've done pouches occur in patients that without inflammatory bowel disease, and in patients with it, you know, looking at hereditary colon cancers, and we're seeing a lot more pouch issues potentially in IBD patients.
- 13:49SPEAKER_01: And so perhaps there's something there that's driving this kind of dual bowel damage bowel layer.
- 13:54SPEAKER_01: Um, and so I think it's really fascinating of what we can do.
- 13:57SPEAKER_01: And I think we the biology tells us that fibrosis can kind of progress silently and kind of kind of underneath our toes before without we're even thinking about it.
- 14:07SPEAKER_01: And it's important to potentially know like how to know which patients are at risk.
- 14:11SPEAKER_01: Certainly not everybody has fibrosis at a baseline, but there's a large proportion of patients that do, and perhaps there's a large proportion instead of patients who have had it for quite some time leading up to it.
- 14:22SPEAKER_01: Um so we want to try to catch it before potentially an irreversible damage or the damage is limited, so that we can have a timed operation or a timed treatment or a prophylactic prevention of the next operation and do this.
- 14:35SPEAKER_01: So, who are we watching for this?
- 14:36SPEAKER_01: Is it what sort of things?
- 14:38SPEAKER_01: You mentioned B1, B2 disease behavior and Crohn's disease.
- 14:41SPEAKER_01: There's potentially that aspect of disease duration, meaning you know, how long the patient's had inflammatory bowel disease diagnosed, Crohn's or ulcerative colitis, the flare history, what those years have been like.
- 14:50SPEAKER_01: Have there been rainy days, have there been sunny days, have there been tornadoes, you know, three every it seems like in Illinois this year or you know, every other weekend.
- 14:58SPEAKER_01: But um, but certainly there, you know, this symptom pattern gets overlooked, you know, and and is there something as an astute clinician over the years that you recognize, you hear that story, and you understand, here's where I could have potentially interlooked?
- 15:09SPEAKER_01: Is it is it just people talking about cramping and bloating without diarrhea, this normal C-reactive protein, normal cal elevated cow protectin?
- 15:17SPEAKER_01: Phil, when that referral lands in your basket with that patient, you know, what tells you, hey, this patient's on the wrong path, we got to take them off the path and get them on the right, on the right place.
- 15:28SPEAKER_02: I mean, yeah, thank you.
- 15:29SPEAKER_02: But I mean, but you know, as a surgeon, by the time that I see them, they've sort of already down that path, having said that.
- 15:36SPEAKER_02: But and I could maybe will bring up an issue regarding the concept of timely early surgery.
- 15:40SPEAKER_02: But the point though is that once they get weight loss, once they get malnutrition, once they're basically a, you know, if they're already cramping significantly and it's interfering with obviously their their quality of life, this is already a red flag.
- 15:52SPEAKER_02: Don't potentially, as I think, as a GI doc, start thinking, my goodness, this is just IBS or this is nothing that we need to worry about.
- 15:59SPEAKER_02: This is something that is already a red flag, what's where this patient is going.
- 16:03SPEAKER_01: Well, absolutely.
- 16:04SPEAKER_01: And and and there's the diagnostic trap, right?
- 16:06SPEAKER_01: We have all these tools, we have all these objective markers, we try to make them into a you know kind of algorithmic way, but we have to, you know, kind of understand the kind of but the things that ride underneath it.
- 16:16SPEAKER_01: You know, so someone having a normal C-reactive protein, borderline caliprotectin, minimal symptoms, and we're somewhat reassured.
- 16:23SPEAKER_01: However, fibrosis, even with those features I mentioned, normal CRP, borderline caliprotectin, minimal symptoms, fibrosis can potentially progress in times of looking at that patient with close clinical symptoms with independence from true inflammatory activity as we have to measure it.
- 16:40SPEAKER_01: Um, and and even when those measures are correct and accurate and precise, which are two different things.
- 16:45SPEAKER_01: Symptoms can appear late.
- 16:47SPEAKER_01: Endoscopy doesn't see the bowel wall.
- 16:49SPEAKER_01: Mucosal healing on the scope does not necessarily confirm this earlier, this whole concept of transmural healing, what kind of goes beyond just the superficial lining of the intestines.
- 17:00SPEAKER_01: Um, and then cross-sectional imaging, you know, I think is a great tool.
- 17:04SPEAKER_01: And that may actually assess the wall.
- 17:06SPEAKER_01: And and Carlos, that's your domain.
- 17:08SPEAKER_01: Let's let's dive into that.
- 17:09SPEAKER_01: Um, I want to get into what we can do and look at it.
- 17:13SPEAKER_01: You you teased something that I have really a poor understanding of, or not as good of understanding of as I want.
- 17:18SPEAKER_01: And you said something like T2.
- 17:19SPEAKER_01: I know that wasn't Terminator 2, T2, T1, weighted, water, fat, fibrosis.
- 17:24SPEAKER_01: You gotta you gotta you gotta translate this for me because I hear from community GI colleagues all what are the imaging modalities we use for Crohn's?
- 17:31SPEAKER_01: What's the best?
- 17:32SPEAKER_01: Um, and the best one is the one that you use, but how can I use each of them the best?
- 17:35SPEAKER_01: Which what do you where do you stand with that, Carl, as from on the other end, as the expert in imaging, abdominal imaging.
- 17:40SPEAKER_03: I use those terms that are so familiar to me, but understand it's not familiar to everyone listening.
- 17:44SPEAKER_03: But to me, it's like, okay, my day-to-day bread and butter description of MR in Crohn's and everywhere.
- 17:50SPEAKER_03: Um let's start with modalities, right?
- 17:53SPEAKER_03: Um wonder is mobile follow-through anymore.
- 17:56SPEAKER_03: You know, this is something that we don't use anymore.
- 17:58SPEAKER_03: But let's talk about the cross-sectional imaging that can really assess blah blah blah a little bit better.
- 18:04SPEAKER_03: Um, MR enterography, and you know, a lot of times it's labeled MRE.
- 18:08SPEAKER_03: I just want to bring the attention to everyone, not to get confused with MR elastography, which is something for fibrosis that we do in the liver.
- 18:16SPEAKER_03: So make sure when you're ordering, you talk about MR enterography for your patient.
- 18:20SPEAKER_03: Uh, then we have CT enterography, we people are more familiar with, and more recently, you know, not more recently, but more frequently used nowadays to inflammatory vowel is intestinal ultrasound.
- 18:33SPEAKER_03: It's pretty, you know, well known for the pediatric population.
- 18:37SPEAKER_03: We use intestinal ultrasound a lot in Pete's cases, but in adults, it has recently become more um used.
- 18:45SPEAKER_03: I tend to think about MRE and CTE in a similar way.
- 18:49SPEAKER_03: Uh, CTE is much more available, it's faster.
- 18:53SPEAKER_03: MRE, though, has that particular capability to see the bowel wall quality, like the tissue quality, and to differentiate the edema versus something that is not necessarily edematous.
- 19:05SPEAKER_03: And that's the T2 signal that I was talking about.
- 19:07SPEAKER_03: Uh T2 basically is a sequence in my that uh evaluates more fluid, fluid sensitive.
- 19:14SPEAKER_03: Basically, anything that is fluid edema is gonna be very bright.
- 19:18SPEAKER_03: Fat can be bright as well, not to be confused, but that's my job to learn and do that.
- 19:22SPEAKER_03: Um, whereas fibrotic changes or things that are not endemic anymore are gonna go towards the dark side.
- 19:30SPEAKER_03: So they go to the dark side, t too dark, more concerning for fibrosis, more concerning for muscular hyperplasia.
- 19:37SPEAKER_03: So these are the things that I tend to look like.
- 19:40SPEAKER_03: Is there a sequence or an exam that is better than another?
- 19:44SPEAKER_03: Uh, as you said, it's best that you can do at least something.
- 19:47SPEAKER_03: Again, CT is very fast.
- 19:49SPEAKER_03: Um, it's a little bit easier to interpret for most people.
- 19:53SPEAKER_03: MR is a little bit more challenging, but has much more information limitations with CT, especially for Crohn's and patients with inflammatory bowel disease.
- 20:02SPEAKER_03: You're gonna have to do longitudinal follow-up.
- 20:04SPEAKER_03: So we want to avoid that radiation.
- 20:06SPEAKER_03: So MR will be preferable in in those patients.
- 20:11SPEAKER_01: Okay, so it's maybe important sometimes to see in reports and look for those things.
- 20:15SPEAKER_01: This is T1, T2, the dark side.
- 20:18SPEAKER_01: I like the dark side thing as a as a Star Wars fan.
- 20:20SPEAKER_01: So we're gonna look away from the dark side.
- 20:22SPEAKER_01: Uh, but certainly it's important.
- 20:23SPEAKER_01: So, Phil, does does you know, CTE, MRE, I mean, even IUS, if we're seeing this, you know, potentially being used, and we'll talk a little bit about that a little later.
- 20:32SPEAKER_01: But does does modality choice matter from your surgical planning perspective?
- 20:37SPEAKER_01: How do you do you look at one?
- 20:38SPEAKER_01: What do you like looking at your imaging?
- 20:40SPEAKER_01: How do you do that?
- 20:41SPEAKER_02: Yeah, I mean it's it's incredibly important.
- 20:43SPEAKER_02: I mean, you know, as surgeons, we need to know geography.
- 20:46SPEAKER_02: That's what we we call the geography of the disease.
- 20:48SPEAKER_02: And we need to, you know, as you know, unfortunately, Crohn's is multi is frequently multi-level disease.
- 20:53SPEAKER_02: So we really need to know where these strictures are, what the distances are between.
- 20:57SPEAKER_02: Are they fibrotic?
- 20:58SPEAKER_02: Are they inflammatory?
- 20:59SPEAKER_02: Sometimes we can't even tell a stricture, quite frankly, in the operating room and rely on what was what was told from us by our radiology colleagues.
- 21:07SPEAKER_02: Uh ultrasound, I think, is a unique thing.
- 21:10SPEAKER_02: Actually, we've been uh toying with intraoperative ultrasound, actually see whether or not that actually would help us in terms of defining what we see.
- 21:16SPEAKER_02: I I totally agree with the concept of trying to avoid CTs in these patients if you can.
- 21:23SPEAKER_02: Um, MRs also are diff on on the other hand, though, MRs are difficult to schedule, at least in our part of the world, a lot more difficult to follow.
- 21:30SPEAKER_02: You know, just from a pure practical point of view, I know it sounds like kind of a silly thing, but I actually like CTs better because I'm sort of used to reading them.
- 21:38SPEAKER_02: I always find when I look at an MR, it looks grainy.
- 21:41SPEAKER_02: And I never look, I never really see the really good stuff that I see on a CT.
- 21:45SPEAKER_02: So that's the reason why, at least myself from a pure selfish point of view, I like teaching residents and fellows I like the CT book.
- 21:51SPEAKER_02: But the MR really has supplanted the uh the at least certainly the routine use of CTE.
- 21:59SPEAKER_01: Definitely some more.
- 22:00SPEAKER_01: images there, Carla, but let me let an MR for sure.
- 22:03SPEAKER_01: But like help us, help us um give us a cheat sheet.
- 22:06SPEAKER_01: Give us the give us the uh the cheat sheet and thing in terms of when that rights study is ordered, interpreting a report is sometimes hard.
- 22:13SPEAKER_01: And for a GI for a GI physician, a GI practitioner, for you know sometimes even potentially our our surgeons who you know are looking at these all the time.
- 22:21SPEAKER_01: How what's like the where do I go to first?
- 22:23SPEAKER_01: What are the real challenges?
- 22:24SPEAKER_01: What findings should I prompt?
- 22:26SPEAKER_01: Like, hey, I I'm hearing this, I'm writing this, some buzzwords, think about when I'm thinking about fibrosis or some potential things, are there anything that I should we should keep it a lookout for?
- 22:36SPEAKER_03: First I have to agree with Vel.
- 22:37SPEAKER_03: CT is a much more ubiquitous and much easier to interpret.
- 22:42SPEAKER_03: Don't get me wrong and yes it's more obvious the uh tissue resolution is better.
- 22:47SPEAKER_03: It is less grainy because it's not as affected by motion and we have to remember Powell moves.
- 22:52SPEAKER_03: You know and we want it to move.
- 22:54SPEAKER_03: So we don't give motion suppression we don't give any drugs because we want to also evaluate the peristalsis when we do in MR.
- 23:01SPEAKER_03: So that's why they don't turn out as beautiful as we wish they were.
- 23:05SPEAKER_03: But the amount of information you can get from it takes time to learn.
- 23:09SPEAKER_03: What should you uh be concerned by when you hear my reporting if I say the wall thickness of a segment that is persistently narrowed in the lumen, if the wall thickness is greater than three millimeters, the T2 signal is dark or low T2 signal or absence of edema, upstream dilatation and recently the SAR, the Society of Abdominal Radiologist had a consensus about when to call dilatation, right?
- 23:36SPEAKER_03: Because that's another gray zone.
- 23:38SPEAKER_03: You know, they want to be more sensitive to avoid delay diagnosing significant restrictors so they decrease the threshold to 2.5 centimeters.
- 23:46SPEAKER_03: So persistent narrow especially if it's a long segment with upstream dilatation of the bow if there's a stasis of contents even better because it shows to you that this has been happening for a while.
- 23:56SPEAKER_03: So it's not just a mirror that this bow is not very spalzing now.
- 24:00SPEAKER_03: These are things to be concerned.
- 24:02SPEAKER_03: One thing to ask your radiologist because some of us are used to describing there's one stricture here, there's another is likely more proximal and another is likely more proximal is the whole length, right?
- 24:13SPEAKER_03: How much of the bowel is involved and how much is not involved in between those segments because Phil cannot go there and resect like this three centimeter stricture leave this two centimeter normal bowel reset the other three centimeter stricture.
- 24:26SPEAKER_03: So the whole segment is actually considered a stricture.
- 24:29SPEAKER_03: So these are things that are important for us to be descriptive and for the surgeons to be aware when we talk about how proximal, how distal, um have a more uniform description.
- 24:39SPEAKER_03: So those are things that I think we know should bring up.
- 24:43SPEAKER_02: If I can be also provocative, I have to tell you that as much as it's very clear you want a dark signal, you want a light signal or whatever it happens to be, I can tell you in the operating room when we do strictroastys, okay, when we do these every single one of those patients has an ulcer left on the anti-mesenteric border when we open up the bowel so there's some degree of inflammation still there.
- 25:05SPEAKER_02: So I I that's why you know when I look at a lot of these the images and they call it I I mean I don't know if you're uh if you're Carl if you're actually just like saying well it's mainly fibrosis but I suspect that the vast majority of the of the of the findings that you see what you call the bland stricture you're probably seeing some signal of inflammation.
- 25:25SPEAKER_03: You're so correct.
- 25:26SPEAKER_03: It's very interesting that you notice that in DOR because for us you know we also are going to look at enhancement pattern, right?
- 25:31SPEAKER_03: So if possible we look at restricted diffusion another word that I know I use a lot easy for me but basically diffusion imaging is a part of MRI that evaluates how water free flows in tissues and usually in healthy tissues it flows okay.
- 25:46SPEAKER_03: In disease tissues, tumors inflammation it kind of gets restricted it cannot move as well.
- 25:52SPEAKER_03: So if there is restriction to us is a sign of some active inflammation.
- 25:57SPEAKER_03: And even in those cases that do have the dark TT wall a lot of times the mucosa or even some part of the cirrhosa has some of that quote unquote inflammatory MR marker.
- 26:07SPEAKER_03: The enhancement pattern is still there the pure fibrotic changes we expect to just enhance on the delayed phase imaging and sometimes we don't see that.
- 26:16SPEAKER_03: You know early enhancement is usually associated with acute inflammation delayed enhancement with fibrosis but most of the times we do have a mixed pattern.
- 26:25SPEAKER_03: Again there's nothing yet in imaging with the current modalities that can confidently tell you with certain this is purely fibrotic.
- 26:36SPEAKER_03: And we also know from some pathology there's a lot of muscle hypertrophy associated with those strictures as well.
- 26:42SPEAKER_03: So tricky by imaging to get with that degree of confidence.
- 26:46SPEAKER_03: So that's why we need to work together.
- 26:49SPEAKER_01: Yeah so I I hear you I hear you're talking about dark and white and then you're talking about gray right in the middle in terms of mixing all these truly what we're looking at in the end, right?
- 26:58SPEAKER_01: And so that's really kind of interesting how that comes together.
- 27:00SPEAKER_01: But I I like I like like Phil's talk of that of that of that ulcerated stenosis which we every so often see and then you're like oh boy this is going to be a problem but you see it on the other, you're seeing it like almost on that dark side of the moon situation where you realize that there's some other things that are on that that are going and speaks of the dual driver of this is fibrosis inflammation different pathway it's just literally proof of it right there that I don't think this is widely discussed and understood and and I'm glad that we're able to kind of dive into this but looking at CT Carla it it's key that the enterography protocol when looking at just CTs versus getting an abdomen pelvis with some IV contrast the enterography protocol is important even when oral contrast is given right some differences there in terms of when you're ordering obviously not a high grade obstruction patient but in a restaging exam is that correct correct no it's very important that you know specifically in uh inflammatory bowel disease and suspicion of uh obstruction it's best that you do an MR or CT enterography right uh the differences of contrast versus a regular CT is that with enterography you give what we call a negative contrast basically the lumen of the bow is going to get a darker contrast because we want a seed enhancement of the wall and if I give the barium or the gastrograph or you know iodine whatever contrast people use in general that's bright that's white and it's going to impair my visualization of that bowel wall enhancement.
- 28:22SPEAKER_03: So that's why we want to have that specific protocol there's a certain volume of contrast that we're gonna need the patient to drink and a certain amount of waiting time in order for the contrast to progress.
- 28:32SPEAKER_03: So the protocol is different and it's important that we follow it in a specific you're looking uh into inflammatory bowel patients.
- 28:40SPEAKER_02: I think that's I would interrupt you but I think that's really important clinically because you know a lot of the GI docs and internists whatever they they rely on the CAT scan that's done in the ED.
- 28:51SPEAKER_02: You cannot rely on that CAT scan done in the ED for the reasons you just mentioned the problem is if you go into an ED, basically you know a little if you have a you know a cut in your finger you're getting an abdominal CAT scan.
- 29:02SPEAKER_02: So by the time we end up seeing them everyone has been radiated already.
- 29:05SPEAKER_01: But you know we've we've been trying to tell our our ER docs, unless you absolutely need the CT right away, wait 24 hours until the next morning to be able to do a CT or an MR if you're able to get that MRE excuse me so that you basically knock off two birds in one stone and not expose the patient to two on to an unnecessary test basically with radiation by the way right tests at the right time that's that's that's the that's a wonderful kind of perfect message that we could really improve and and and decrease a lot of unnecessary and and and you know spending and scans that aren't helping us frankly sometimes but um can I I want to go back to something Carla mentioned about this consensus update on and and Phil maybe you can help us kind of drive this into from the from the surgeon's perspective stricture length pre-senotic dilatation there are numbers everywhere can you help us put that a stricture is two centimeters long and the vowel is this much in front of it what does this all mean to you?
- 29:59SPEAKER_01: What sort of things do you use and and does this make sense to you and I like that the threshold's now smaller uh so to speak but how how what do you how does this how does this ring for you?
- 30:09SPEAKER_03: Carly want to take it first yeah well uh the uh standardization of description is not there yet there are a lot of consensus trying to get people to follow certain standards and as I mentioned previously uh the degree of dilatation is something we're being more sensitive and less specific so we're decreasing anything that is greater than 2.5 centimeters uh upstream from an area of persistent narrowing with wall thickening is considered a significant or a stricture uh absence of passage of a scope even if I don't see upstream dilatation if they tell me like you know what I couldn't pass my scope through the TI even if I look at the TI looks okay there's no upstream dilatation it's a red flag you know there's probably a stricture there um wall thickening greater than three millimeters and important to understand that you have to have adequate distinction of bowel right because the bow is collapsed there can be a confusion oh yeah this is thickened it's not necessarily so make sure the bowel has adequate distinction throughout uh the signal on on the wall is another thing that that we look at um and the length of stricturing to me is important so I can tell Dr.
- 31:24SPEAKER_03: Flashner to either go aro ahead and try a strictoplasty or just resect it but you know if I see anything that is narrowed I feel compelled to describe persistent narrowing especially important if I have a longitudinal follow-up if I can see how this has progressed over time or if it has changed or improved.
- 31:41SPEAKER_02: Yeah I I I agree with all of that and I I I certainly you know this is one of the problems we have we don't have a good definition of what a significant stricture is and that's led to a significant concern that we have when we design studies to try to figure out what's your endpoint.
- 31:55SPEAKER_02: What are you trying to do?
- 31:56SPEAKER_02: What are you trying to prevent?
- 31:57SPEAKER_02: What is really a significant stricture like we always talk for example in the surgical field about upstream dilatation proximal dilatation but what's that number?
- 32:06SPEAKER_02: You know sometimes the radiologist I look at it and it's like the size of your head they're not even describing it as proximal dilatation.
- 32:12SPEAKER_02: So I think you have to be really careful and no one really knows the exact number just like Carlos said.
- 32:17SPEAKER_02: I guess it goes I guess in the clinical context of what's going on with the patient.
- 32:21SPEAKER_02: But you know usually now I think we're sort of getting to the center just like Carlos said two and a half, three centimeters, you're sort of in the area now where this is considered upstream dilatation.
- 32:29SPEAKER_02: And upstream dilatation is an extremely important finding at least for surgeons as well because we know from our literature and our understanding that once you get proximal dilatation the chance of that patient needing surgery within a year is extremely high.
- 32:42SPEAKER_02: And you know that that that's a negative prognostic sign for that patient.
- 32:46SPEAKER_02: So you can continue your medical therapy if you need to but really the the GI doc should be considering hey maybe this is a signal here that I should stop and start over if you like and you know basically stop putting the patient through the conundrum you know the whole can the whole circus of medication like we talked about before.
- 33:03SPEAKER_01: Yeah sometimes that reset like you said can can can really can really be kind of transformative um for uh for patients and and truly probably happens at the at the uh conglomeration of of the imaging um gastroenterology colorectal surgery altogether um come working and so forth so I'll you know it's important to realize that some of these scans you know when they uh uh occur outside specialized IBD centers or with that uh imaging protocols that um we want to make sure that the right test is done at the right time for the for the right patient and um and kind of tells us you know some things.
- 33:34SPEAKER_01: Let's let's dive into the couple clinical scenarios um and just to kind of put some of this kind of translated to what we potentially could see in the clinic or um um in in on the way to the operating room.
- 33:44SPEAKER_01: So 36 year old woman ileal colonic Crohn's disease on us to kinemab for eight years few symptoms CRP is normal cow protectance 290 so elevated there's intermittent intermittent and postprandial cramping and bloating bloating uh no significant diarrhea two flares in the last four years requiring cortical steroids as a rescue no cross sectional imaging in four years Carlo Phil Carlo what would you what do you what do you think?
- 34:14SPEAKER_03: You know me I'm an imagery right show me the money I want to see it where is it what's happening to the patient honestly I tend to you know when I do my first look at any of my patients I ignore some of the clinical findings because I want to go in with no bias.
- 34:28SPEAKER_03: I want to see it.
- 34:29SPEAKER_03: So um but yes I want to see what's going on there that maybe it's the nose is stricter there uh there may be superimposed inflammation I I need to see it.
- 34:37SPEAKER_02: MRE please MRE therapy I I agree with that and you know there's something going on here.
- 34:44SPEAKER_02: I mean postpanal cramping that's responsive like these if you understand if I understand the scenario to steroids if I understand when the patient had a flare that's not that's not normal.
- 34:53SPEAKER_02: That's not continuous pain like you get with a perforation is example.
- 34:57SPEAKER_02: And so something's going on here and you know the fact that the patient has any has not any cross-sectional imaging in four years is kind of a little concerning.
- 35:05SPEAKER_02: Listen you can also do the other things are you having you're hearing you know noises when you're eating is your belly getting is your abdomen becoming distended those are the other things that you can literally don't even have to order a you know a$2500 test.
- 35:17SPEAKER_02: You can say something's going on although you still want the MRE but at least it'll actually you know force you to actually hey this really is significant.
- 35:25SPEAKER_03: I love what you think about hearing the noises because in MR we do a sequence that is actually a Cine image.
- 35:31SPEAKER_03: You can see the bowel moving you can see peristalsis and that's exactly how when I see how I picture the patient you know when I see like excessive peristalsis upstream from an air that they're now the bow is trying to go through I'm like they're probably hearing this gurgling and that's what they feel it's cramping because it's trying to push through.
- 35:49SPEAKER_01: That's truly dynamic imaging and you can hear the sounds of the image up there.
- 35:54SPEAKER_01: That's fantastic.
- 35:54SPEAKER_01: I love that I've not heard that before and someone describing what you're seeing from your perspective and and to our GI guys it's probably answers not scope them anymore.
- 36:03SPEAKER_01: It's get some scans get some imaging please to get the answers to where to go or we can try.
- 36:09SPEAKER_01: Yeah but it but it's true like see go on and Phil like minimal symptoms the competition you know the does that change your assessment I mean I think we have some markers that show that there's a problem here and and this was Phil you highlighted it eight years this is an advanced therapy a current advanced therapy that's on board is the kinemab but this patient's still having all these problems we're still banging through we're falsely reassured of what's going on and and we're not recognizing the problem sometimes until you know until hopefully the right scenario they're seeing us and and and getting an imaging that Carla's going to read so let's see okay let's move on let's move on to another scenario 52 year old man small bowel crowns 18 years of disease worsening postprandial pain and nausea eight pound weight loss over three months CRP is mildly elevated cow protectin's elevated the albumin's three point one the MRE shows 12 centimeters of aneleal stricture up with upstream dilatation low T2 signal or suggestive of fibrotic predominance no active fistula and the patient's on vitalismab for 18 months or year and a half prior to that was on adolimimab which was stopped for quote unquote secondary loss of response Carla what is this what is it can you tell me about that imaging study you say you low I said it's low T2 walk us through that again that that low T2 signal right the dark side always favoring more that fibrotic or you know muscular hypertrophy process going on uh one caveat always always always in this patient since it's also temporal differences in uh inflammatory bowel disease always tell my residents make sure you look at the whole bowel don't be happy because you found that stricture right the obvious finding look back and look at everything make sure there's nothing else temporally different or an additional area that suggests stricture because once they go to the OR, you want to guide the surgeon to be as fast as possible and as objective as possible, right?
- 38:04SPEAKER_03: So if I have two either temporally different uh processes going on or two strictures that are remote from each other, I like to guide my surgeon say hey there's this obvious one that everyone can see but you know look a little more approximately because there's this other smaller area that I'm uh a little concerned as well.
- 38:20SPEAKER_03: But yes based on this findings alone uh I would uh tell my doctors maybe this one isn't one that's not going to improve with just medication.
- 38:30SPEAKER_02: Bill the upstream dilatation length yeah uh this patient needs surgery I mean you know I mean I mean I mean quite frankly what happens in the real world as opposed to you know most GI docs will now go on to the you know you know the next MOA and see what's going on and realizing this next sort of what we talked about before we're going down the wrong the you know the bad rat you know rat hole here in terms of rabbit hole what's going on.
- 38:51SPEAKER_02: So really what needs to get done this patient needs a surgical evaluation okay and um quite frankly don't screw around in any more medication at this patient.
- 39:01SPEAKER_02: I mean the other thing you should consider by the way which is not and not likely but a possibility is you know these patients get cancer too don't forget about that and you know that doesn't necessarily mean that's an absolute prime indication for surgery but don't think that these patients that should always be sort of in the back of your mind particularly with this longstanding disease.
- 39:18SPEAKER_01: Oh that's a great point in terms of looking 18 years 50 over 50 I know we're straddling that range and that's a huge huge thing to think about and an absolute great great thing to keep in mind.
- 39:28SPEAKER_01: I'm I'm gonna zag a little bit and and Phil you said something really a little earlier about um you know MRI straight and it's fantastic right now we're magically blessed with Carla coming in on call at 3 a.m to read this MRE as we've done for technically and we're trying to get MREs done and and and I think there's a timing for that but what do you I do you think this is somewhere where in that clinic and that exposure to an intestinal ultrasound that we're able to see you know some of this stuff real time at the bedside in a properly trained person, you know, integrating this at an IBD clinic with a direct quick referral to surgery and then maybe getting it a with a positive a positive test getting an you know an MRE if needed to fully highlight things do you think that there's some potential benefit there with this and bowel wall assessment, radiation free, quick point of care monitoring, direct quick referral to an operation before we're thinking about different therapies or before we can fast track an MRE in that situation.
- 40:20SPEAKER_01: Do you think this could potentially work?
- 40:22SPEAKER_02: Well I think it does work.
- 40:23SPEAKER_02: I've seen it work in our clinic it works.
- 40:25SPEAKER_02: You know when when I look at these ultrasound I'm looking at these guys looking at differences of like 0.1 millimeter like one millimeter in the bowel wall and say come on guys I mean really like you know this is like fantasy land you could really make a difference a differentiation of the wall but they can and they're very reliable and their interobserver reliability is very high.
- 40:42SPEAKER_02: So it's it's an amazing technology and as you said all the reasons you said point of care no radiation simple to do you're literally in the clinic you see what's going on these are these are the patients that either need to go see you know a surgeon or potentially even you know they'll probably need an MRE if they haven't had any recent imaging but if this patient has you know patient has proximal dilatation bowel wall thickening basically you're seeing this on ultrasound send a patient to the surgeon you see it right there simple cost is like almost nothing Carla Yeah um I agree intestinal ultrasound in the good hands in a good patient is amazing.
- 41:23SPEAKER_03: A few caveats though guest is the enemy of ultrasound so the upstream bowel sometimes is very difficult for whoever is doing the ultrasound to evaluate everything.
- 41:34SPEAKER_03: But once you see there's so many things you can do right you see that segment of bow that is abnormal um there are so many new uh research on even elastography which is something that we do for the liver uh in to evaluate fibrosis in the liver they're applying it to the bowel wall as well under ultrasound guidance so it can be you know has so much potential but there is limitations we just have to be aware of them and whenever you know we have questions or to further evaluate the extent of disease uh sometimes an additional uh cross-sectional imaging such as MR uh or even CT is recommended but in the good hands ultrasound is really amazing we have an amazing IBD team here that they do their own ultrasounds and you know we show each other the cases and sometimes the correlation is so perfect with my MR.
- 42:19SPEAKER_03: I'm like you're not gonna need me anymore.
- 42:22SPEAKER_01: It'll be a good good competitive uh uh yeah education augmenting care I think and and learning learning more um from the mapping phil I'm gonna I'm gonna pivot here and and and take us through like the surgic surgical decision let's pretend that that that last scenario or another scenario let's say I see that person I let's say I make the right decision that hey I need to see the patient needs to see Dr.
- 42:43SPEAKER_01: Fleshner.
- 42:44SPEAKER_01: So a gastronologist is going to be like oh I'm gonna help you in the meantime I'm gonna give you some steroids to bridge you and you're probably gonna need an operator maybe what do you what do you do what do you don't tell me what you really think but tell me what you really think uh in that situation what do we need to do this do we what should we do?
- 42:58SPEAKER_02: Really think you're out of your mind but actually having said that I would not say that publicly like that but having said that um it's just not well thought out you know you know if you look at surgical morbidity all the things that that that the GI docs are giving it's not the advanced therapies it's not the biologics it's not the small molecules what it is actually is steroids.
- 43:21SPEAKER_02: Steroids are the worst drug you can possibly give you know I always tell my residents and my my fellows you know if steroids went in front of the FDA now it would never be approved because of all the side effects.
- 43:32SPEAKER_02: In fact the stuff side effects that we see I forget all the other stuff that you guys see in terms of GI doc but the stuff that we see anastomotic dehistons, wound infections, SSIs, et cetera, et cetera, that's all in many, many ways attributable to the misuse of steroids.
- 43:48SPEAKER_02: And particularly in a scenario like this where the patient doesn't absolutely need steroids, you're not doing anything for us as surgeons to try to downstage the disease by giving the steroids and all you end up doing is putting the patient at a Higher surgical morbidity.
- 44:01SPEAKER_02: It's all you're doing.
- 44:04SPEAKER_01: I love that.
- 44:04SPEAKER_01: That's huge.
- 44:05SPEAKER_01: And you know, then there's this, there's this, you we mentioned this earlier about, you know, about some some important trials.
- 44:11SPEAKER_01: And I think there are probably two that we want to think about.
- 44:14SPEAKER_01: And one of them, we'll start with the we'll start with the first one in that Puccini trial, really addressing, addressing some of this perioperative complication steroids are making the problem.
- 44:23SPEAKER_01: Can you tell us a little bit about what that meant for you in practice, what that was like when that when that came up?
- 44:27SPEAKER_01: What do you think about that?
- 44:28SPEAKER_02: Yeah, I was actually one of the authors on that trial.
- 44:30SPEAKER_02: So let me tell you the story with with this with this the whole thing that came out when advanced initially when Infliximab came out.
- 44:38SPEAKER_02: You know, there's no question it plays a role in all these medications and somewhat in wound healing.
- 44:42SPEAKER_02: And some of the data that came out suggested there was an increase in astomotic leak rates and all CSSIs.
- 44:48SPEAKER_02: But literally, it was the worst science, like typical surgical science that like is just crap, quite frankly.
- 44:54SPEAKER_02: Okay.
- 44:54SPEAKER_02: Retrospective patient selection, go on and on and on.
- 44:58SPEAKER_02: So what happened was that there was a study that was done, the Puccini trial, which is a multi-centered trial of almost a thousand patients that looked at the influence of, in particular, TNF and uh uh TNF inhibition, and looked at surgical morbidity.
- 45:11SPEAKER_02: And there was absolutely no effect whatsoever whether or not the patient was on TNF uh inhibitors or not.
- 45:17SPEAKER_02: The surgical morbidity was the same.
- 45:19SPEAKER_02: So this has nothing to do with the medication.
- 45:22SPEAKER_02: And the reason that's important to just from a GI point of view is that you know, sometimes the surgeon will come up to you and say, you know, you put that patient on advanced therapies and now the patient leaked, that's your fault.
- 45:32SPEAKER_02: That's actually not your fault.
- 45:34SPEAKER_02: That's actually the surgeon's fault.
- 45:36SPEAKER_02: Okay.
- 45:36SPEAKER_02: Now you can argue that maybe the patient was malnourished and anemic and all those other things, but to tell you to ascribe this potential leak that the surgeon wants to deflect blame onto the GI doc for the leak, you can say, excuse me, sir, look or ma'am, look at the Putini trial.
- 45:50SPEAKER_02: That's not the case.
- 45:52SPEAKER_01: Optimizing patients perioptively, you there are there's certain tenets in terms of this prehab.
- 45:57SPEAKER_01: You know, what does it look like in practice?
- 45:59SPEAKER_01: What are you doing in the weeks before the incision and when planning and planning?
- 46:04SPEAKER_02: Yeah, so you know, we always think the the way that I explain it to patients, which I think is understandable, is we want it's basically optimization.
- 46:11SPEAKER_02: The way I tell the patient it's not rehab, it's prehab.
- 46:15SPEAKER_02: Okay, it's done before.
- 46:16SPEAKER_02: And there's many different facets of it.
- 46:18SPEAKER_02: Stop smoking, get your sugar under control, weight loss, which sometimes is hard because the patients are on steroids, get off steroids or minimize the amount of steroids, which sometimes is hard to do, as you know.
- 46:29SPEAKER_02: But one of the probably the most important part of prehab is exercise.
- 46:34SPEAKER_02: And what I tell my patients to do is I tell them to get on a treadmill every day for 20 minutes, just put incline five or 10 and just walk.
- 46:43SPEAKER_02: Get sweaty, get short of breath.
- 46:44SPEAKER_02: And the way that you kind of uh tell it to the patient is it's very similar to what your body is going to end up doing when it's had uh stress during surgery.
- 46:52SPEAKER_02: And it's been shown, it's particularly in some of our in some of our data, to improve surgical morbidity.
- 46:57SPEAKER_02: The cost of it is zero.
- 46:59SPEAKER_02: There's no side effects.
- 47:00SPEAKER_02: In fact, if anything, it makes patients healthier because they exercise more.
- 47:03SPEAKER_02: So that's one of the really important things about trying to get these patients optimized as best you can, particularly the exercise part.
- 47:11SPEAKER_01: All right.
- 47:12SPEAKER_01: So we need to move it.
- 47:12SPEAKER_01: I like that's fascinating and a great great message.
- 47:15SPEAKER_01: I like that.
- 47:16SPEAKER_01: Phil, Phil, 60 seconds, um, maybe even less.
- 47:20SPEAKER_01: The single most important thing GI physicians get wrong in the lead-up to IBD surgery.
- 47:27SPEAKER_02: Probably the most important thing is the concept of this is a non-surgical disease, and I have to continue to use my medications till the cows come home.
- 47:37SPEAKER_02: And it only at the end do I have to call, you know, the you know, the green, you know, the uh, you know, the surgeon, the king surgeon to come in and sort of fix up, you know, mop up the problem.
- 47:46SPEAKER_02: I think that's a mistake.
- 47:47SPEAKER_02: This concept of uh of using just the last resort, I think, as well, you know, just to let you know very quickly, Crohn's disease was initially a surgical disease.
- 47:56SPEAKER_02: The initial approach of that was surgery.
- 47:58SPEAKER_02: But the problem is they got a lot of the patients got short balance, you know.
- 48:00SPEAKER_02: Why?
- 48:01SPEAKER_02: Because by the time that the surgeon saw it, they had you know feet upon feet upon disease and the medications then came up.
- 48:07SPEAKER_02: Now there's this concept of trying to do early surgery.
- 48:09SPEAKER_02: There's this thing called, for those who don't know, there's this thing called a lyric trial, which is a randomized trial, really good level in evidence, showing the value, not only in terms of cost, not only in terms of quality of life, but the ability to stay off medications and in maybe of some way reset the disease that you're in in these patients, that actually suggests that actually earlier, at least we call it now timely surgery, is the best way to go.
- 48:34SPEAKER_03: I'm going just to chime in as the radiologist on the group.
- 48:38SPEAKER_03: Um, one thing that some people learn in the very remote path is avoid surgery because of that, right?
- 48:46SPEAKER_03: And nowadays, with better imaging and uh anal analyzing patients individually, I think it's just a matter of timely surgery.
- 48:54SPEAKER_03: You know, don't wait, do it when you can and image somewhat frequently to be able to know that, right?
- 49:03SPEAKER_00: Yeah, absolutely.
- 49:04SPEAKER_02: But again, it's not it's not only good, but it's better.
- 49:07SPEAKER_02: I think that's the key.
- 49:08SPEAKER_02: The lyric trial showed that the certain the results of of the cer of surgery were better 10 years.
- 49:13SPEAKER_02: So that it's it's not only good, it's better.
- 49:15SPEAKER_02: And by the way, it doesn't only lyric applied to ileocolacromies, luminal disease.
- 49:19SPEAKER_02: There's also some very good evidence that the same concept applies to perienal disease.
- 49:24SPEAKER_02: Stop screwing around with cetons and then pulling the cetons out and continuing the medications when you think, in fact, the fistula is healed.
- 49:31SPEAKER_02: You can ask Carla, many of those are not healed on MR and they remain symptomatic and come back.
- 49:36SPEAKER_02: In fact, there's some evidence that by going in surgically and attacking them surgically early is actually better for the patient.
- 49:43SPEAKER_02: And you get better MRI healing, better MRI for fibrosis.
- 49:48SPEAKER_01: Yeah, I mean, I'm talking 10-year therapy-free remission, you know, a difference of delta of over 20%.
- 49:53SPEAKER_01: Um, and and that's what showed in those right patients.
- 49:56SPEAKER_01: I think their trial definitely has a lot of potential benefit, massive lots of benefit.
- 50:00SPEAKER_01: You know, and even operations, all operations, not all IVD surgery isn't the same.
- 50:04SPEAKER_01: Of course not.
- 50:05SPEAKER_01: You know, there's resection, there's strict chlasty.
- 50:07SPEAKER_01: Are there different options when stricted lengths are different and you use imaging to potentially help plan some of that?
- 50:13SPEAKER_01: And sometimes there are interoperative decisions on some of that as well.
- 50:15SPEAKER_01: And do you have a favorite or a go-to in the right situation?
- 50:18SPEAKER_01: Um, and looking at different different methods of stricturoplasty.
- 50:23SPEAKER_02: Yeah, well, you know, that's a that's where interoperative judgment and experience come together as an IBD surgeon.
- 50:29SPEAKER_02: You know, you it's you have a you have a whole cornucopia of resection techniques, including something called the cono S and extended mesosenteric dissection, many have heard about, which I'm not going to get into right now.
- 50:39SPEAKER_02: But the point is that there's many different ways to do a resection.
- 50:42SPEAKER_02: There's many different ways to do a strictroplast.
- 50:44SPEAKER_02: The IBD surgeons, hopefully, are experienced, should be, should know about this.
- 50:48SPEAKER_02: Quite frankly, sometimes you use them both.
- 50:50SPEAKER_02: You can use a resection in one part of the intestine and a strictoplastin in the other part of the of the intestine.
- 50:55SPEAKER_02: So these are the kind of things that actually, you know, almost a hybrid approach where the judgment comes in.
- 51:00SPEAKER_02: And this is where, you know, I've always promoted the idea that, you know, if you have a pancreatic tumor, don't come to me.
- 51:05SPEAKER_02: Go go to the people who do a lot of pancreatic surgery.
- 51:08SPEAKER_02: If you have an IBD problem, come to me, go to the people, and you know, hopefully the GI docs will know that as well.
- 51:13SPEAKER_02: Send those patients to IBD surgeons who know what they're doing because there's a lot of intraoperative judgment, placing bullets in between to see where there's stricture, where there's not, you know, looking using intraoperative ultrasound, all those kind of little things that make an enormous difference.
- 51:27SPEAKER_02: They don't sound like a lot, but they end up making an enormous difference in the patient's outcome.
- 51:32SPEAKER_01: Surgery doesn't always mean resection, it doesn't always mean losing bowel, maybe gaining gaining quality of life and gaining improvement, perhaps.
- 51:39SPEAKER_01: And it's what I'm live what I'm lifting from what you're seeing there.
- 51:41SPEAKER_01: Um and that that's uh that's a that's a huge point.
- 51:45SPEAKER_01: I think something that we have to counsel our patients together um a little better um to make sure we have this is done.
- 51:51SPEAKER_01: So let's do some.
- 51:52SPEAKER_01: I'm gonna do some rapid fire as we've kind of near the end of our end of our discussion here.
- 51:56SPEAKER_01: So first instinct, one line, no explanation.
- 51:59SPEAKER_01: Um, both of you where it's relevant.
- 52:00SPEAKER_01: You guys ready?
- 52:02SPEAKER_03: Let's do it.
- 52:03SPEAKER_01: Okay.
- 52:04SPEAKER_01: Patient has mucosal healing and biologics, persistent prosprandial cramping, reassure or re-image?
- 52:11SPEAKER_03: MR.
- 52:12SPEAKER_03: Enterography.
- 52:14SPEAKER_02: And or MRE.
- 52:16SPEAKER_01: Pre-stenotic dilatation on MRE in a biologic refractory patient, medical optimization or surgical consult.
- 52:26SPEAKER_03: I'll send it to him.
- 52:28SPEAKER_02: Surgery assuming the disease segment is short.
- 52:31SPEAKER_02: Yes.
- 52:33SPEAKER_01: GI physician wants to give pre-operadnisone to control inflammation before bowel resection.
- 52:38SPEAKER_01: Yes or no?
- 52:39SPEAKER_03: We just heard no, even for the radiologist to learn that.
- 52:45SPEAKER_01: Phil's work here is done.
- 52:47SPEAKER_01: We're turning him for Phil to an F-word.
- 52:48SPEAKER_01: He's antifibrosis.
- 52:50SPEAKER_01: No, no, stereo.
- 52:51SPEAKER_01: Yes, I love it.
- 52:52SPEAKER_02: Love Fleshner.
- 52:53SPEAKER_02: It's an F-word.
- 52:54SPEAKER_02: It's an F-word.
- 52:54SPEAKER_02: Yes, it is.
- 52:55SPEAKER_01: Let's go, Fleshner.
- 52:56SPEAKER_01: Yes.
- 52:56SPEAKER_01: We had the F-word in.
- 52:58SPEAKER_01: Anti-TNF within 12 weeks of surgery.
- 53:01SPEAKER_01: Safe or not safe?
- 53:02SPEAKER_00: I have to pass.
- 53:04SPEAKER_01: Safe.
- 53:04unknown: Okay.
- 53:05SPEAKER_01: Safe.
- 53:06SPEAKER_01: Safe.
- 53:06SPEAKER_01: Okay.
- 53:07SPEAKER_01: Albumin 2.8.
- 53:08SPEAKER_01: Electrive stricter plasty in two weeks.
- 53:10SPEAKER_01: Operate now or optimize first.
- 53:14SPEAKER_02: One-word answer, optimize now.
- 53:16SPEAKER_02: But just to let you know very quickly, albumin is a very poor marker, as everyone knows, of nutrition, so a malnutrition.
- 53:22SPEAKER_02: So assuming that you're that's what you're getting to, optimize.
- 53:25SPEAKER_02: Okay.
- 53:26SPEAKER_01: T2 signal on MRE.
- 53:29SPEAKER_01: Reliable fibrosis marker or not yet?
- 53:32SPEAKER_03: Not yet.
- 53:32SPEAKER_03: Getting there.
- 53:33SPEAKER_01: Okay, okay.
- 53:34SPEAKER_01: So we're we're getting that from the late afternoon into the primetime spot.
- 53:38SPEAKER_01: All right.
- 53:38SPEAKER_01: If anyone even watches TV anymore.
- 53:40SPEAKER_01: Lyric at 10 years.
- 53:42SPEAKER_01: Does it change how you counsel a patient about early surgery?
- 53:46SPEAKER_00: One word.
- 53:47SPEAKER_00: Yes.
- 53:47SPEAKER_00: It's uh but it you know it gets backs to Carla's point, though.
- 53:52SPEAKER_02: Carla, Carla said it.
- 53:54SPEAKER_02: Most patients still are of the fundamental understanding, either because what they've read or quite frankly, what their GI docs have told them, that you shouldn't have surgery unless you absolutely have to, which is why we need you, GI docs, to help us kind of continue this lyric process.
- 54:08SPEAKER_02: Sorry, sorry about the sorry sorry about the lack of one-word answer.
- 54:11SPEAKER_01: No, no, that's great.
- 54:12SPEAKER_01: Embrace it.
- 54:13SPEAKER_01: Embrace it.
- 54:14SPEAKER_01: One word to describe from both you guys why structural IBD gets missed for too long.
- 54:23SPEAKER_03: Unawareness.
- 54:25SPEAKER_01: I agree with that.
- 54:26SPEAKER_01: Okay, double down.
- 54:28SPEAKER_01: Pocket tens, we got it.
- 54:29SPEAKER_01: All right.
- 54:30SPEAKER_01: So just with that, um, before we close, you know, the horizon, um, five areas where the science is moving, antifibrotic targets in the preclinical and early phase pipeline, immunofibrosis targeting, where Talissa Cobard has now shown phase three efficacy in UC with Crohn's data still pending, mesentery and creeping fat, as we heard Phil said earlier, as a fibrotic fibrotic compartments that current therapies don't reach.
- 54:55SPEAKER_01: You know, AI-assisted imaging may help for automated fibrosis quantification with guidance and and and potentially expanding upon this oversimplification, perhaps sometimes of this treat to target and expanding that towards transmural healing will is something that we need to anticipate.
- 55:11SPEAKER_01: Phil, if antiphibrotic agents that address both inflammation and fibrosis simultaneously reach the clinic, does that change surgical volumes?
- 55:19SPEAKER_00: What do you think?
- 55:20SPEAKER_00: I think it's going to end up reducing it, which is good, of course.
- 55:23SPEAKER_00: I think so.
- 55:25SPEAKER_01: Carla, transmural healing is emerging as a treat-to-target endpoint in trials.
- 55:30SPEAKER_01: From the imaging side, how close are we to being able to define and measure it reliably?
- 55:35SPEAKER_01: How close are we to you being able to help us with this?
- 55:38SPEAKER_03: You know, things are moving so fast, especially in the research uh setting.
- 55:42SPEAKER_03: I'm hoping that within the next five years we'll have more quantitative and more reliability.
- 55:46SPEAKER_03: Uh, but that would depend a lot on instabilization, right?
- 55:49SPEAKER_03: Of my reporting, everyone else's reporting.
- 55:51SPEAKER_03: So we don't have just uh consensus findings, but level one evidence uh of what we're seeing.
- 55:57SPEAKER_03: Um but yeah, there is magnetization transfer, there is you know new uh pet biomarkers that we can try to image in fibrosis and healing.
- 56:06SPEAKER_03: So there are things in the horizon that I'm hopeful for.
- 56:09SPEAKER_01: Yeah, and hope hopefully scaling intestinal ultrasound more widespread as a quick access to patients getting the right care and quick surgical consultation when needed and looking when therapies may not be the right medical treatment, medications may not be the answer all the time, um, which is what now we're kind of primed in IBD, but certain, certainly the current ones, and we're anticipating hopefully that you know potentially can prevent the next operation with the right antifibrotics, and and Phil, you kind of spoke to that a little bit.
- 56:35SPEAKER_01: So hopefully, hopefully there's some something there.
- 56:37SPEAKER_01: So if I if you had to finish this sentence, each of you, the thing that would most change how IBD structural disease is managed starting tomorrow is multidisciplinary approach.
- 56:50SPEAKER_01: Pretty much what Carl said.
- 56:51SPEAKER_01: Okay.
- 56:52SPEAKER_01: Excellent.
- 56:53SPEAKER_01: Well, hey, thank you both.
- 56:54SPEAKER_01: Um, to our learners, fibrosis in IBD is not inevitable and it's not invisible if you use the right tools, ask for the right reports, and act before your patient obstructs, order the right imaging, specify IBD-focused radiology review, stop the steroids before surgery, and don't wait for symptoms before you send a surgical referral.
- 57:17SPEAKER_01: Recognize early, monitor structurally, and treat before the window closes.
- 57:21SPEAKER_01: And with that, I'll share with you a few smart goals that you can implement to put information into action.
- 57:26SPEAKER_01: When you get back to your practice, try to increase the use of cross-sectional imaging, MRE or CT enterography, that's MR enterography or CT enterography, for IBD patients with symptom biomarker discordance or high-risk clinical features rather than relying only on labs and symptoms alone.
- 57:46SPEAKER_01: Improve documentation of fibrosis risk factors, including disease duration, prior flares, phenotype at each IBD visit to support really an earlier identification of patients who may benefit from structural reassessment and importantly apply a structured approach to interpret radiology reports in IBD, including stricture characterization, upstream dilatation, and that T2 signal to guide timely medical optimization or surgical consultation.
- 58:16SPEAKER_01: For additional resources, visit www.cmeoutfitters.com for clinical information and certified educational activities and the gastroenterology hub.
- 58:26SPEAKER_01: To receive CME or CE credits for this activity, participants must complete the post-test and evaluation online.
- 58:32SPEAKER_01: Participants will be able to download and print their certificate immediately upon completion.
- 58:37SPEAKER_01: And remember, this is the second of a three-part podcast series on IBD.
- 58:41SPEAKER_01: I'm also hosting two additional episodes Beyond Symptoms, The Hidden Burden of IBD, and the Future of Disease Modification, as well as Extraintestinal Manifestations in IBD, screening, referral triggers, and multidisciplinary care pathways.
- 58:55SPEAKER_01: And I hope you'll be able to join us.
- 58:57SPEAKER_01: Thank you, and we'll see you next time.